I am working in Tom Blundell's group as postdoctoral research associate. My project is centered around fragment-based drug design to interrupt/inhibit the interaction of Hepatocyte Growth Factor/Scatter Factor (HGF/SF) with its receptor MET. This pathway is involved in cancer metasasis and has emerged as a prominent drug target in recent years. Apart from trying to crystallise MET with inhibitors I am also doing functional assays in cells and biophysical experiments to characterise my compounds. My project is funded by the EU until end of September 2011.